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Abstract
Introduction Adenine nucleotide translocator (ANT) 2 is highly
expressed in proliferative cells, and ANT2 induction in cancer
cells is known to be directly associated with glycolytic
metabolisms and carcinogenesis. In addition, ANT2 repression
results in the growth arrest of human cells, implying that ANT2
is a candidate for cancer therapy based on molecular targeting.
Methods We utilized an ANT2-specific RNA interference
approach to inhibit ANT2 expression for evaluating its antitumor
effect  in vitro and  in vivo. Specifically, to investigate the
therapeutic potential of ANT2 repression, we used a DNA
vector-based RNA interference approach by expressing shRNA
to knockdown ANT2 in breast cancer cell lines overexpressing
ANT2.
Results ANT2 shRNA treatment in breast cancer cell line MDA-
MB-231 repressed cell growth as well as proliferation. In
addition, cell cycle arrest, ATP depletion and apoptotic cell
death characterized by the potential disruption of mitochondrial
membrane were observed from the ANT2 shRNA-treated breast
cancer cells. Apoptotic breast cancer cells transfected with
ANT2 shRNA also induced a cytotoxic bystander effect that
generates necrotic cell death to the neighboring cells. The
intracellular levels of TNFα and TNF-receptor I were increased
in ANT2 shRNA transfected cells and the bystander effect was
partly blocked by anti-TNFα antibody. Ultimately, ANT2 shRNA
effectively inhibited tumor growth in vivo.
Conclusion These results suggest that vector-based ANT2
RNA interference could be an efficient molecular therapeutic
method for breast cancer with high expression of ANT2.
Introduction
Apoptosis can occur via a death receptor-mediated pathway
or a mitochondrial pathway, and mitochondria-mediated apop-
tosis is initiated by multiple stimuli such as TNF, CD95 and
stresses [1]. After receiving apoptotic signals, mitochondrial
membrane permeability increases and the mediators such as
cytochrome c and apoptosis-inducing factors are released to
the cytoplasm, rapidly followed by the activations of caspase
9 and executive caspase 3 [2]. In healthy cells, mitochondrial
membrane permeability is tightly controlled by voltage-
dependent anion channels that are regulated by the interac-
tions between Bcl2 family proteins [3,4].
Adenine nucleotide translocase (ANT) is a nuclear-encoded
protein abundantly located in the inner mitochondrial mem-
brane, and the role of this protein is to catalyze the exchange
of mitochondrial ATP with cytosolic ADP. ANT therefore plays
an important role in cellular energy metabolism by influencing
mitochondrial oxidative phosphorylation. In addition, ANT is
the major component of mitochondrial permeability–transition
pore complex (PTPC) that interacts with Bcl2 family proteins,
thereby contributing to mitochondria-mediated apoptosis
[4,5]. ANT-deficient mice are able to form mitochondrial PTPC
[6], however, inducing the argument about the roles of ANT in
mitochondrial PTPC.
ANT = adenine nucleotide translocator; BSA = bovine serum albumin; DMEM = Dulbecco's modified Eagle's medium; dsRNA = double-stranded 
RNA; FBS = fetal bovine serum; IFN = interferon; IL = interleukin; iRNA = interfering RNA; PBS = phosphate-buffered saline; PCR = polymerase 
chain reaction; PI = propidium iodide; PTPC = permeability–transition pore complex; RT = reverse transcription; shRNA = short-hairpin RNA; siRNA 
= small interfering RNA; TNF = tumor necrosis factor.Breast Cancer Research    Vol 10 No 1    Jang et al.
Page 2 of 14
(page number not for citation purposes)
Human ANT has four isoforms (ANT1, ANT2, ANT3 and
ANT4) and the relative expressions of these isoforms are
dependent on developmental stages, proliferation status as
well as tissue types or cell types. ANT3 is ubiquitously
expressed in all tissues and the degrees of ANT3 expression
are correlated with the levels of oxidative metabolism. ANT1 is
highly expressed in terminally differentiated tissues such as
skeletal muscles, heart and brain, whereas ANT4 is a murine
stem and germ cell-specific isoform whose DNA methylation
plays a key role in its transcriptional silencing in somatic cells
[7,8]. On the other hand, ANT2 is specifically expressed in
undifferentiated cells or tissues that are able to proliferate and
regenerate; for example, the lymphocytes, kidney and liver [9-
11]. The expression of ANT2 was recently found to be upreg-
ulated in several hormone-dependent cancers [12], and the
induction of ANT2 expression in cancer cells was directly
associated with glycolytic metabolisms, raising a question
regarding the role of ANT2 during carcinogenesis [13-16].
Indeed, the overexpressions of ANT1 or ANT3 induce apopto-
sis while ANT2 lacks this proapoptotic activity [17,18]. ANT2
repression also leads to cell growth arrest and increases mito-
chondrial membrane potential from human cells as well as
chemosensitized cancer cells [10,12], implying that ANT2
inhibits mitochondrial membrane permeability and acts as an
antiapoptotic oncoprotein. We therefore hypothesized that
ANT2 can be a promising candidate for cancer therapy based
on specific molecular targeting.
iRNA is currently used for knockdown of a particular gene
expression to identify the functions of a targeted gene and to
examine the potential usage of a targeted gene as a therapeu-
tic method. iRNA is an evolutionarily conserved phenomenon,
and a multistep process produces active siRNA from RNase III
endonuclease (Dicer). The consequent 21-nucleotide to 23-
nucleotide siRNAs then mediate the degradation of comple-
mentary homologous RNA [19-21]. Two basic methods have
currently been developed to selectively inhibit gene expres-
sion: the cytoplasmic delivery of short dsRNA oligonucle-
otides (siRNAs) that mimic the active intermediates of
endogenous iRNA; and the nuclear delivery of gene expres-
sion cassettes encoding shRNAs that imitate micro iRNAs
representing the active intermediates of different endogenous
iRNA mechanisms. The mechanisms of DNA vector-based
approaches involve the synthesis of small RNA from a DNA
template under the control of RNA polymerase III (Pol III) pro-
moter in transfected cells. Pol III has an advantage for directing
the synthesis of small noncoding transcripts whose 3' ends
are defined by the termination within a stretch of four to five
thymidines [22-25]. These properties allow us to use DNA
templates for generating small RNAs in vivo [26] whose struc-
tural features are close to the active siRNAs synthesized in
vitro. The DNA vector-based iRNA approach can therefore be
used widely for analyzing gene functions in vitro as well as in
vivo [27-29].
In the present article we investigate the anticancer effects of
ANT2 RNA interference in breast cancer models in vitro and
in vivo using a DNA vector-based (H1-driven shRNA) iRNA
approach. Our results demonstrate that the silencing of ANT2
expression using a DNA vector-based iRNA approach induces
apoptotic cell death and cytotoxic bystander effects that elicit
anticancer activity in vitro as well as tumor regression in vivo,
implicating that the repression of ANT2 based on shRNA can
be a novel method for breast cancer therapy.
Materials and methods
Cell lines and culture
The human metastatic breast carcinoma cell lines MCF7 and
MDA-MB-231 as well as ovarian cancer cell lines SK-OV-3
and SNU8 were used throughout the study. These cells were
provided by the Korean Cell Line Bank, Seoul, Korea and were
cultured in DMEM supplemented with 10% FBS, 100 u/ml
penicillin and 100 μg/ml streptomycin. MCF-10A, a line of
healthy epithelial cells from human mammary gland (CRL-
10317) provided by the American Type Culture Collection
(Manassas, VA, USA) was used as a control. This cell line was
maintained in the DMEM/Ham's Nutrient Mixture F-12 (1:1)
with the addition of epidermal growth factor (20 ng/ml), chol-
era enterotoxin (100 ng/ml), insulin (10 μg/ml) and hydrocorti-
sone (500 ng/ml) in the presence of 5% horse serum.
Construction of the ANT2 siRNA expression vector
ANT2 siRNA-1, siRNA-2 and siRNA-3 were synthesized by
Bioneer (Daejeon, Korea), and pSilencer™ 3.1-H1 puro plas-
mids for DNA vector-based siRNA synthesis were purchased
from Ambion (Austin, TX, US). The oligonucleotide pairs of
ANT2 siRNA-1, siRNA-2, and siRNA-3 are complementary to
exon 2 or exon 4 (Genbank accession number NM001152),
and the sequences of ANT2 siRNA-1, siRNA-2 and siRNA-3
are 5'-GCAGAUCACUGCAGAUAAGTT-3', 5'-CTGACAT-
CATGTACACAGG-3' and 5'-GATTGCTCGTGATGAAGGA-
3', respectively. The oligonucleotide pairs were designed to
contain a terminal BamHI or HindIII restriction site for subclon-
ing into the BamHI or HindIII site of pSilencer™ 3.1-H1 puro
vector to generate pSilencer™ 3.1-H1 puro ANT2 siRNA vec-
tors (shRNAs). These vectors produce a shRNA with a
TTCAAGAGA linker sequence that forms looped structures.
This linker is processed with Dicer to generate an ANT2-spe-
cific siRNA. A negative scrambled siRNA (Ambion) control
with no significant homology to mouse or human gene
sequences was designed to detect nonspecific effects.
Transfection
For transfection, cells were plated on either six-well plates (2
× 105 cells per well) or 100 mm dishes (2 × 106 cells) and
were allowed to adhere for 24 hours. Lipofectamine 2000 (Inv-
itrogen, Carlsbad, CA, USA) was used for the transfections.
pSilencer™ 3.1-H1 puro ANT2 siRNA vectors or pSilencer™
3.1-H1 puro scramble siRNA vector were transfected into the
cells. Transfected cells were then cultured for 4 hours and theAvailable online http://breast-cancer-research.com/content/10/1/R11
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culture media were replaced with fresh media supplemented
with 10% FBS. The cells were harvested at 24–48 hours after
transfection.
Reverse transcription-polymerase chain reaction
After 48 hours of transfection, the cells were collected and
total RNA was extracted using Trizol (Invitrogen) according to
the manufacturer's instructions. For RT-PCR analysis, 5 μg
total RNA was reverse-transcribed using RT-PCR kits
(Promega, Madison, WI, USA). PCR was used to amplify tar-
get cDNA with the following conditions: 35 cycles of 94°C for
1 minute, 55°C for 1 minute and 72°C for 2 minutes. The PCR
products were analyzed using standard agarose gel
electrophoresis.
The primers used for RT-PCR are ANT1 forward, 5'-ACA-
GATTGTGTGGTTT-3' and reverse, 5'-TTTTGTGCATTAAGT-
GGTCTTT-3' ; ANT2 forward, 5'-
CCGCAGCGCCGGAGTCAAA-3' and reverse, 5'-AGTCT-
GTCAAGAATGCTCAA-3' ; ANT3 forward, 5'-AACCAAGA-
GAACCACGTAGAA-3' and reverse, 5'-
CTTAGAACAGACTTGGCTC-3' ; TNF-receptor I forward, 5'-
CTGCCTCAGCTGCTCCAAA-3' and reverse, 5'-CGGTC-
CACTGTGCAAGAAGAG-3' ; and β-actin forward, 5'-
GGAAATCGTGCGTGACATTAAGG-3' and reverse, 5'-
GGCTTTTAGGATGGCAAG GGA C-3'.
Western blotting
Anti-ANT, anti-Bcl-xL, anti-Bax, anti-α-tubulin as well as anti-
caspase-3 antibodies were obtained from Santa Cruz Biotech
(Santa Cruz, CA, USA) and polyclonal anti-ANT3 antibody
was donated by Dr HH Schmid (University of Minnesota, MN,
USA).
For western blot analyses, cells were harvested after 48 hours
of transfection and were lysed with lysis buffer (5 mM/l ethyl-
enediamine tetraacetic acid; 300 mM/l NaCl; 0.1% NP-40;
0.5 mM/l NaF; 0.5 mM/l Na3VO4; 0.5 mM/l phenylmethylsulfo-
nyl fluoride; and 10 μg/ml each of aprotinin, pepstatin and leu-
peptin; Sigma, St Louis, MO, USA). After centrifugation at
15,000 × g for 30 minutes, the concentrations of supernatant
proteins were analyzed by Bradford reagent (Bio-Rad, Her-
cules, CA, USA).
For the analysis of protein contents, 50 μg total proteins was
electrophoresed in 10% SDS-PAGE gel, transferred to polyvi-
nylidene difluoride membranes (Millipore, Bedford, MA, USA)
and were then incubated with the respective antibodies indi-
cated above. Immunoblots were visualized using an enhanced
chemiluminescence detection system (Amersham Pharmacia
Biotech, Uppsala, Sweden).
Apoptosis and DNA fragmentation assays
Approximately 2 × 105/ml MDA-MB-231 cells were trans-
fected with respective pSilencer™ 3.1-H1 puro ANT2 siRNA-
1, siRNA-2 and siRNA-3 vectors as well as with pSilencer™
3.1-H1 puro scramble siRNA vector for the indicated times.
The transfected cells were harvested, washed twice with PBS
and were then incubated for 15 minutes at room temperature
with a solution of annexin V conjugated with fluorescence iso-
thiocyanate (2.5 μg/ml) and propidium iodide (PI) (5 μg/ml)
(BD Pharmingen, San Diego, CA, USA) for flow cytometry
(Epics XL; Coulter, Marseille, France) to detect the levels of
apoptosis. Genomic DNA was extracted using genomic DNA
extraction kits (G-DEX™IIc; Invitrogen, Seoul, Korea) and was
subjected to electrophoresis in 2% agarose gels for DNA frag-
mentation analysis.
ATP assay
ATP assays were conducted using CellTiter-Glo™ Lumines-
cent Cell Viability assay kits (Promega) that quantify ATP levels
in viable cells. This bioluminescence assay utilizes luciferase,
which induces light emission during the interaction between
ATP and luciferin. Lyophilized enzyme/substrate mixtures (250
μl) were transferred to opaque 96-well microplates containing
cell lysates. The plates were incubated at room temperature
for 10 minutes to stabilize luminescence signals and then the
stabilized signals were quantified with an Orion Luminometer
(Berthold Detection Systems, Oak Ridge, TN, USA).
Cell cycle analysis
The cells transfected with pSilencer™ 3.1-H1 puro ANT2
siRNA or pSilencer™ 3.1-H1 puro scramble siRNA vector
were trypsinized, counted, centrifuged and fixed in ethanol for
3 hours. These cells were then washed twice in PBS and cen-
trifuged. Pellets were resuspended with a solution containing
RNase (0.02 mg/ml) (Sigma), incubated at 37°C for 30 min-
utes and were stained with PI (0.02 mg/ml) (Sigma). The cells
were analyzed by flow cytometry (Epics XL; Coulter).
Measurement of mitochondrial membrane potentials
To measure mitochondrial membrane potential disruption, the
cells transfected with pSilencer™ 3.1-H1 puro ANT2 siRNA or
pSilencer™ 3.1-H1 puro scramble siRNA vector were har-
vested, washed twice with PBS and were incubated with 20
nM 3,3'-diethyloxacarbocyanine (Molecular Probes, Eugene,
OR, USA) for 15 minutes at 37°C. Mitochondrial membrane
potential values were determined by flow cytometry (Epix XL;
Coulter).
In vitro bystander effect assays
MDA-MB-231 cells (1.5 × 103) were cultured with the culture
media of pSilencer™ 3.1-H1 puro ANT2 siRNA-1/siRNA-2/
siRNA-3-transfected cells for 24 hours and were then har-
vested. Cell death was determined by annexin V–fluorescence
isothiocyanate/PI staining followed by flow cytometry analysis
(Epics XL; Coulter).Breast Cancer Research    Vol 10 No 1    Jang et al.
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Fluorescent-activated cell sorter analysis (intracellular 
and surface staining)
Respective pSilencer™ 3.1-H1 puro ANT2 siRNA-1, siRNA-2
and siRNA-3 vectors as well as pSilencer™ 3.1-H1 puro
scramble siRNA vector were transfected into MDA-MB-231
cells for the indicated times. Six hours before harvesting, the
cells were treated with brefeldin A (10 μg/ml), washed twice
with PBS, fixed with 2% paraformaldehyde, permeabilized
with buffer (1% BSA, 0.1% saponine, 0.1% sodium azide in
PBS) and were then stained with phenylethylene-conjugated
anti-TNFα, anti-IFNγ, anti-IL-12 as well as anti-mouse IgG anti-
bodies for 1 hour at 4°C (BD Pharmingen). Surface staining
was performed with phenylethylene-conjugated anti-TNF-
receptor 1 as well as anti-mouse IgG antibodies and then ana-
lyzed by flow cytometry (Epics XL; Coulter).
Antitumor effect of ANT2 iRNA in vivo
For tumor challenges, we established tumor models in 6-week-
old to 8-week-old Balb/c nude mice by subcutaneously inject-
ing 5 × 106 MDA-MB-231 cells into the right flanks. Treat-
ments were started from 2 weeks after tumor inoculation when
tumor volumes were <100 mm3. Intratumoral injections of
PBS, pSilencer™ 3.1-H1 puro scramble siRNA vector (100
μg) or respective pSilencer™ 3.1-H1 puro ANT2 siRNA-1,
siRNA-2 and siRNA-3 supplemented with Lipofectamine
2000 (200 μl) were performed three times per day for 5 days.
Tumor sizes were measured using a caliper every week until
56 days after tumor challenges, and tumor volumes calculated
using the formula: m1
2 × m2 × 0.5236 (where m1 represents
the shortest axis and m2 the longest axis)
In situ detection of apoptosis detection
In situ detection of apoptosis was performed using ApopTag
Fluorescein (Intergenco, New York, USA). After the blocking
of endogenous peroxidase with 3% hydrogen peroxide for 5
minutes, the sections were digested with proteinase K (20 μg/
ml) for 15 minutes at room temperature and were then treated
with bovine testicular hyaluronidase (0.5 mg/ml) for 30 min-
utes at 37°C. DNA was end-labeled with deoxynucleotidyl
transferase-mediated dUTP nick end-labeling and was
detected with peroxidase-conjugated antidigoxigenin anti-
body. The reactivity was visualized by the mixtures of diami-
nobenzidine and hydrogen peroxide.
Statistical analysis
Data were analyzed using the Student's t test. P < 0.05 was
considered statistically significant.
Results
ANT2 expression markedly upregulated in human breast 
cancer cell lines and efficiently suppressed by RNA 
interference
To explore the functions of ANT2 in cancer, we first examined
its mRNA expression levels in human cancer cell lines
obtained from various organs (Figure 1a). RT-PCR showed
that ANT2 mRNA was expressed in various human cancer
cells originated from the stomach, lung, liver, ovary and breast.
ANT2 mRNA was dramatically overexpressed in human breast
cancer cell lines (MCF7, MDA-MB-231 and SK-BR-3) and
was overtly increased in ovarian cancer cell lines (SK-OV-3
and SNU8), however, suggesting that overexpression of ANT2
could be a unique feature of breast cancer and ovarian cancer
that may play a role in cancer development.
To expand the knowledge of ANT mRNA expressions among
breast cancer cell lines, the MCF7 and MDA-MB-231 cell
lines, as well as the non-neoplastic mammary epithelial cell line
MCF10A, the relative expressions of three ANT isoforms from
these cell lines were investigated at mRNA and protein levels
(Figure 1b). In terms of mRNA expressions, ANT2 is highly
expressed in both breast cancer cell lines while ANT1 and
ANT3 expressions are not detectable. In contrast, the non-
neoplastic MCF10A cell line barely expresses ANT2 as well as
ANT1 but highly transcribes ANT3. Serendipitously, the tran-
scriptional patterns of ANT isoforms in ovarian cancer cell line
SK-OV-3 are identical to breast cancer cell lines (Additional
File 1a), emphasizing the significance of ANT2 overexpression
in breast cancer cells and ovarian cancer cells.
ANT2 protein levels were also tested from the breast cell lines
by western blotting (Figure 1b). Owing to the absence of
ANT1-specific and ANT2-specific antibodies, however, the
protein levels of ANT2 were indirectly detected by subtracting
the amount of ANT3 from total ANT protein levels. The total
protein levels of ANT in respective breast cell lines are about
the same, but ANT3 protein is not detectable from the breast
cancer cell lines. On the other hand, ANT3 protein is domi-
nantly expressed in the non-neoplastic MCF10A cell line
where ANT3 mRNA is highly expressed. This result suggests
that the breast cancer cell lines have more ANT1 and ANT2
proteins than ANT3 proteins. No ANT1 mRNA is detectable
from both breast cancer cell lines, however, indicating the
majority of ANT proteins in breast cancer cell lines might be
ANT2 proteins. Collectively, these arrays of results suggest
that the higher expression of ANT2 in breast cancer and ovar-
ian cancer cell lines is a unique feature that may play a key role
in cancer development.
Owing to the unique feature of overt ANT2 overexpression in
breast cancer and ovarian cancer cell lines, we hypothesized
that the downregulation of ANT2 in these cell lines may induce
serious physiological effects that result in cell growth inhibition
or cell death. To evaluate the functions of ANT2 in cancer
development or the possible utility of ANT2 downregulation for
breast cancer therapy, therefore, ANT2-specific knockdown
experiments were performed with human breast cancer cell
lines. Initially, respective siRNA-1, siRNA-2 and siRNA-3 oligo-
nucleotides directed at exon 2 or exon 4 of ANT2 mRNA were
synthesized to determine whether ANT2 siRNA suppresses
ANT2 expression. At the same time, DNA oligonucleotidesAvailable online http://breast-cancer-research.com/content/10/1/R11
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representing the siRNA duplex were cloned into pSilencer™
3.1H1 puro vector to produce a high-level silencing effect
based on a DNA vector system. The synthesized shRNA
derived from DNA templates was composed of two identical
21-nucleotide sequence motifs in an inverted orientation, sep-
arated by a 9 base pair nonhomologous spacer (shRNA).
To confirm the silencing efficacies of ANT2 siRNA-1, siRNA-2
and siRNA-3 as well as pSilencer™ 3.1H1-ANT2 siRNA
(ANT2 shRNA-1, siRNA-2 and siRNA-3), the cell lines MCF7
and MDA-MB-231 were transfected with the above samples
as well as scramble siRNA and pSilencer™ 3.1H1-scramble
siRNA (scramble shRNA) as negative controls. After culturing
Figure 1
Expression and silencing efficiency of adenine nucleotide translocator 2 in cancer cell lines Expression and silencing efficiency of adenine nucleotide translocator 2 in cancer cell lines. Expression of adenine nucleotide translocator (ANT) 2 in 
cancer cell lines and the silencing efficiency of ANT2 siRNA and shRNA in human breast and ovarian cancer cell lines. (a) RT-PCR analysis for 
detecting ANT2 mRNA expression in various human cancer cell lines. To evaluate ANT2 expression levels in the human cancer cell lines of various 
origins (SNU668, SNU719, SNU638, NCI-H358, A549, NCI-H889, SK-HEP-1, SNU449, SNU423, SK-OV-3, SNU8, SNU840, MCF7, MDA-MB-
231 and SK-BR-3), total RNA was extracted from respective cell lines and subjected to RT-PCR using specific primers for human ANT2 or β-actin 
(internal control). (b) RT-PCR analysis and western blotting to detect ANT isoform expressions in breast cancer cell lines as well as a non-neoplastic 
breast cell line. To compare ANT isoform mRNA levels in non-neoplastic breast epithelial cell line MCF10A with other breast cancer cell lines such 
as MCF7 and MDA-MB-231, total RNA was extracted from the respective cell lines and subjected to RT-PCR using specific primers for human 
ANT1/ANT2/ANT3 or β-actin. In addition, to detect ANT protein levels, total cell extracts were used for performing western blotting with anti-ANT, 
anti-ANT3 and anti-β-actin antibodies. (c) RT-PCR analysis and western blotting for detecting the level of ANT2 repression mediated by ANT2 
siRNA and ANT2 shRNA. To assess the extinction of endogenous human ANT2 mRNA in MCF7 and MDA-MB-231 cells due to ANT2 RNA interfer-
ence, respective cell lines were transfected with ANT2 siRNAs, ANT2 shRNAs, scramble siRNA as well as scramble shRNA for 48 hours. Total RNA 
was then extracted from respective samples and subjected to RT-PCR using specific primers for human ANT2 or β-actin. To indirectly detect the 
reduction of ANT2 protein by ANT2 RNA interference, MCF7 cells were transfected with ANT2 shRNA-1, shRNA-2 and shRNA-3 as well as scram-
ble shRNA, and 48 hours later total cell extracts were collected for performing western blotting with anti-ANT and anti-β-actin antibodies.Breast Cancer Research    Vol 10 No 1    Jang et al.
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for 48 hours, their efficacies in extinguishing ANT2 mRNA
expression were evaluated by RT-PCR. As shown in Figure 1c,
the treatment with ANT2 shRNA was much more effective
than the treatment with ANT2 siRNA in terms of downregulat-
ing the ANT2 mRNA level. Treatment with ANT2 shRNA for 48
hours decreased ANT2 mRNA expressions in MCF7 and
MDA-MB-231 cells by over 90% compared with the cells
transfected with control vectors, while ANT2 siRNA treatment
resulted in markedly less reduction. The total protein levels of
ANT were also downregulated by ANT2 shRNA, indirectly indi-
cating that the knockdown of ANT2 reduces the protein levels
of ANT2 (Figure 1c). These results suggest that ANT2 shRNA
is superior to ANT2 siRNA for downregulating ANT2 mRNA as
well as protein levels and can be used to target ANT2 for
breast cancer therapy.
Taken together, we have uniquely identified the higher expres-
sion of ANT2 mRNA from human breast cancer cell lines
MCF7, MDA-231 and SK-BR-3 as well as ovarian cancer cell
lines SK-OV-3 and SNU8. To investigate the possible utility of
ANT2 downregulation as a cancer therapy, ANT2 shRNA sys-
tems were adopted and the actual downregulation of ANT2
mRNA as well as protein mediated by ANT2 shRNA was con-
firmed from human breast cancer cell lines. As a result, we
established a shRNA system to investigate the therapeutic
value of ANT2 downregulation in breast cancer in vitro and in
vivo.
ANT2 depletion induces cell cycle arrest (G1 arrest) and 
apoptotic cell death in vitro
To explore the potential of ANT2 shRNA as a treatment for
human breast cancer, the diverse phenotypic changes of
respective cancer cell lines affected by ANT2 shRNA were
investigated. Firstly, the cell survival and proliferation rate were
investigated using MDA-MB-231. After transfecting MDA-MB-
231 cells with ANT2 shRNA-1 for 24 hours, the transfected
cells became less confluent as compared with the cells trans-
fected with scramble shRNA. Many ANT2 shRNA transfected
cells even became rounded and detached from culture plates,
providing one line of evidence about cell death or cell cycle
arrest (Figure 2a). In addition, the proliferation rate of ANT2
shRNA-1 transfected MDA-MB-231 cells was also obviously
reduced (Figure 2b). To understand the effects of ANT2
shRNA in MDA-MB-231 cells more specifically, the levels of
intracellular ATP and the cell cycle status in transfected cells
were investigated. Intracellular ATP levels were significantly
reduced by up to 50% in the cells transfected with ANT2
shRNA-1 (Figure 2c), suggesting the death of ANT2 shRNA
transfected cells is ascribed to the reduction of ATP synthesis.
Cell cycle analysis indicated that the G1 populations of ANT2
shRNA-treated MDA-MB-231 cells were 12% (24 hours) and
14.6% (48 hours), while scramble shRNA-treated cells dis-
played 0.8% (24 hours) and 7.6% (48 hours) of the G1 popu-
lations (Figure 2d). Additional analysis gating on the sub-G1
population also showed similar results after 24 or 48 hours of
transfection, indicating ANT2 shRNA induces G1 arrest in
breast cancer cells.
We finally tested whether the knockdown of ANT2 shRNA
induces cell death in the breast cancer cell lines MCF7 and
MDA-MB-231 in vitro. Based on annexin V and PI staining,
both ANT2 siRNA and ANT2 shRNA increased early apoptotic
cells (AV+PI-), intermediate apoptotic cells (AV+PI+) as well as
late apoptotic cells (AV-PI-) compared with control groups
after 48 hours of transfection (Figure 2e). ANT2 shRNA was
more effective than ANT2 siRNA, however, in terms of induc-
ing cell death. For example, ANT2 siRNA induced around 25–
35% of cell death, while ANT2 shRNA generated about 50–
60% of apoptotic cells. These results coincide with our previ-
ous observation regarding the higher efficacy to suppress
ANT2 expression by ANT2 shRNA than ANT2 siRNA as
shown in Figure 1c, suggesting increased ANT2 downregula-
tion induces more cell death. Additionally, the ovarian cancer
cell lines SK-OV-3 and SNU8 transfected with ANT2 siRNA or
shRNA demonstrated similar results to those obtained from
the breast cancer cell lines (Additional File 1b). These results
imply that the physiological effects of ANT2 downregulation
could be consistent in both cancers.
Taken together, these results suggest that the downregulation
of ANT2 efficiently inhibits cell growth and proliferation by
reducing ATP levels as well as inducing G1 arrest, which ulti-
mately leads to the apoptosis of human breast cancer cells in
vitro.
ANT2 shRNA induces apoptosis by reducing the 
membrane potential of mitochondria and activating 
caspase 3 in MDA-MB-231 cells
To confirm apoptosis was responsible for the cell death
induced by ANT2 shRNA in breast cancer cell lines, we exam-
ined the presence of genomic DNA fragmentation. As we
expected, DNA laddering – a characteristic of apoptotic cell
death – was abundantly observed from ANT2 shRNA-1 trans-
fected MDA-MB-231 cells (Figure 3a), proving the death of
transfected cells mediated by ANT2 shRNA is apoptotic.
It has been reported that Bcl-2 family molecules can physically
interact with ANT and that this interaction regulates ANT-
mediated mitochondrial permeability transition pore formation
[7]. To understand the mechanisms of apoptosis induced by
ANT2 shRNA, we examined the changes of Bcl-2 family pro-
tein levels during the ANT2 shRNA-1-induced, shRNA-2-
induced and shRNA-3-induced apoptosis in MDA-MB-231
cells by western blotting. The transfection of ANT2 shRNA-1,
shRNA-2 and shRNA-3 resulted in the upregulation of Bax
(proapoptotic) and the downregulation of Bcl-xL (antiapop-
totic) (Figure 3b). In addition, caspase-3 activation – defined
by the appearance of cleaved caspase 3 – was observed from
ANT2 shRNA-treated cells. These results clearly demonstrate
that ANT2 shRNA induces the apoptosis via the Bcl-2 family.Available online http://breast-cancer-research.com/content/10/1/R11
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Figure 2
Apoptotic changes of human breast cancer cell lines transfected with adenine nucleotide translocator 2 shRNA Apoptotic changes of human breast cancer cell lines transfected with adenine nucleotide translocator 2 shRNA. (a) Cell morphology analysis: MDA-
MB-231 cells were transfected with scramble shRNA or adenine nucleotide translocator (ANT) 2 shRNA-1 and then examined under a phase con-
trast microscope after 24 hours of transfection. (b) Cell proliferation assay: after 2 or 4 days of transfection with ANT2 shRNA-1 as well as scramble 
shRNA, the numbers of viable cells were determined using a hemacytometer after staining dead cells with Trypan Blue. (c) ATP assay: cells were 
transfected with ANT2 shRNA-1 as well as scramble shRNA and then lysed to quantify total intracellular ATP levels after 24 hours of incubation. 
Results are tabulated in relative ATP production by normalizing luminescence units (RLU) with total protein levels. (d) Cell cycle analysis: after 24 or 
48 hours of transfection with scramble shRNA and ANT2 shRNA-1, the cells were trypsinized, fixed in ethanol and stained with propidium iodide to 
determine DNA contents. Cell cycle distributions were analyzed by flow cytometry. (e) Apoptosis analysis: cells were transfected with specific 
siRNA or shRNA against ANT2, and then 48 hours later the transfected cells were stained with annexin V–fluorescence isothiocyanate (FITC) and 
propidium iodide (PI) for flow cytometry analysis. Data are representative of three independent experiments.Breast Cancer Research    Vol 10 No 1    Jang et al.
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We assumed the apoptosis triggered by ANT2 shRNA must
be involved in the mitochondria-mediated apoptotic pathway
because ANT2 protein is abundant in mitochondrial mem-
branes. The potentials of mitochondrial membranes were
measured by 3,3'-diethyloxacarbocyanine staining to prove
our hypothesis. As expected, the cells transfected with ANT2
shRNA-1 displayed about 10-fold shifted curves to the left
after 24 and 48 hours of transfection, indicating that mitochon-
drial membrane potentials are disrupted in apoptotic cells
transfected with ANT2 shRNA (Figure 3c).
Taken together, these results implicate that ANT2 shRNA
changes the Bcl-2 family balance in mitochondrial mem-
branes, favoring a proapoptotic pore-forming status, and
thereby causes the disruption of mitochondrial membrane
potentials resulting in cell apoptosis.
Figure 3
Adenine nucleotide translocator 2 shRNA regulated Bcl-2 family members and disrupted mitochondrial membrane potentials Adenine nucleotide translocator 2 shRNA regulated Bcl-2 family members and disrupted mitochondrial membrane potentials. Adenine nucleotide 
translocator (ANT) 2 shRNA regulated the levels of Bcl-2 family members and disrupted mitochondrial membrane potentials to induce apoptosis in 
MDA-MB-231 cells. (a) DNA laddering assay: cells were transfected with ANT2 shRNA-1, and then 48 hours later total genomic DNA was extracted 
and subjected to electrophoresis in 2% agarose gel to examine DNA fragmentation patterns. (b) Western blotting for identifying apoptotic mecha-
nisms: cells were transfected with ANT2 shRNA-1, shRNA-2 and shRNA-3. Cytoplasmic extracts (free of mitochondria) were prepared after 24 
hours of incubation for performing western blotting with anti-Bax, anti-Bcl-xL, anti-cleaved caspase 3 and anti-α-tubulin antibodies. (c) Analysis for 
detecting mitochondrial membrane potential: cells were transfected with ANT2 shRNA-1, and then 24 or 48 hours later the transfected cells were 
stained with 3,3'-diethyloxacarbocyanine. Mitochondrial membrane potentials were quantified by flow cytometry. Data are representative of three 
independent experiments.Available online http://breast-cancer-research.com/content/10/1/R11
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Cell death by ANT2 shRNA amplified by the cytotoxic 
bystander effect in MDA-MB-231 cells
Before transfecting MDA-MB-231 cells with ANT2 shRNA-1,
shRNA-2 and shRNA-3, we also assessed transfection
efficiencies using GFP (Green Fluorescence Protein)-express-
ing vector. Although the transfection efficiency was only about
30%, the proportion of cells killed by ANT2 shRNA treatment
exceeded 60%, raising the possible existence of bystander
effect. To confirm the presence of a bystander effect in MDA-
MB-231 cells, we cultured nontransfected cells with the
supernatants obtained from ANT2 shRNA-1, shRNA-2 and
shRNA-3 transfected cells and then evaluated cell death by
annexin V–PI staining.
As shown in Figure 4, nontransfected cells cultured with the
supernatants from ANT2 shRNA-1, shRNA-2 and shRNA-3
transfected cells committed to cell death defined by AV-PI+.
The absence of DNA laddering and the lack of an AV+ popula-
tion lead us to consider that necrosis might be the major
mechanism of cell death induced by this bystander effect.
These results therefore suggest that cytotoxic agents must be
secreted from ANT2 shRNA-transfected cells to the media.
Bystander effect associated with TNFα production and 
increased TNF-receptor I expression in ANT2 shRNA 
transfected cells
To determine the cause of this bystander effect, we examined
the levels of proinflammatory cytokines such as TNFα, IFNγ
and IL-12 from MDA-MB-231 cells treated with ANT2 shRNA
or scramble shRNA by intracellular fluorescent-activated cell
sorter. TNFα expression was elevated eight-fold in the cells
treated with ANT2 shRNA-1 but the levels of IFNγ and IL-12
Figure 4
Adenine nucleotide translocator 2 shRNA induced cytotoxic bystander effects on MDA-MB-231 cells Adenine nucleotide translocator 2 shRNA induced cytotoxic bystander effects on MDA-MB-231 cells. To evaluate bystander effects, MDA-MB-231 
cells were transfected with adenine nucleotide translocator (ANT) 2 shRNA-1, shRNA-2 and shRNA-3. After 48 hours of incubation, nontransfected 
cells were cultured with the media obtained from ANT2 shRNA-1, shRNA-2 or shRNA-3 transfected cells for the next 24 hours. These nontrans-
fected cells were then stained with annexin V–fluorescence isothiocyanate (FITC) and propidium iodide (PI) for flow cytometric analysis. Data are 
representative of three independent experiments.Breast Cancer Research    Vol 10 No 1    Jang et al.
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were unchanged (Figure 5a).
In addition, we evaluated TNF family death receptor I expres-
sion by RT-PCR and flow cytometry. Both transcription and
surface expression of TNF-receptor I were upregulated by the
transfection with ANT2 shRNA (Figure 5b). Additionally, the
bystander effect was partially neutralized by anti-TNFα anti-
body (Figure 5c). These results suggest that the observed
bystander effect might be caused by TNFα secretion and TNF-
receptor I expression.
ANT2 shRNA inhibits tumor growth in vivo
We finally evaluated the antitumor effects of ANT2 shRNA in
vivo using a nude mouse tumor xenograft model. Tumor sizes
Figure 5
Bystander effects generated in MDA-MB-231 cells associated with TNFα production and TNF-receptor I expression Bystander effects generated in MDA-MB-231 cells associated with TNFα production and TNF-receptor I expression. Bystander effects generated 
by adenine nucleotide translocator (ANT) 2 shRNA in MDA-MB-231 cells were associated with TNFα production and TNF-receptor I (TNFRI) 
expression. (a) Intracellular staining of TNFα, IFNγ and IL-12 p40. Cells were transfected with ANT2 shRNA-1. After 48 hours of incubation, the 
transfected cells were treated with brefeldin A for the next 6 hours. The cells were harvested, fixed in paraformaldehyde and then stained with phe-
nylethylene-conjugated anti-TNFα, IFNγ or IL-12 p40 as well as anti-mouse IgG antibodies (negative control). Intracellular levels of TNFα, IFNγ and 
IL-12 p40 were analyzed by flow cytometry. (b) RT-PCR and fluorescent-activated cell sorter analysis for detecting the expression of TNFRI at tran-
scriptional and translational levels. Cells were transfected with ANT2 shRNA-1. After 24 hours of incubation, total RNA was extracted and subjected 
to RT-PCR using specific primers for human TNFRI and β-actin. The RT-PCR products were analyzed by 1% agarose gel electrophoresis. In addi-
tion, the surface expression of TNFRI was measured by flow cytometry after staining cells with phenylethylene-conjugated anti-TNFRI antibody. (c) 
Partial neutralization of bystander effect mediated by anti-TNFα antibody. Cells were transfected with ANT2 shRNA-1. After 48 hours of incubation, 
the supernatants were collected and then mixed with or without TNFα antibody before transferring into nontransfected cells. These nontransfected 
cells were cultured for the next 24 hours and stained with annexin V–fluorescence isothiocyanate (FITC) and propidium iodide (PI) for flow cytomet-
ric analysis.Available online http://breast-cancer-research.com/content/10/1/R11
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were measured twice per week and the observations lasted
over 56 days after tumor challenge with MDA-MB-231 cell
lines. Tumor growth was significantly inhibited in ANT2
shRNA-1-treated, shRNA-2-treated and shRNA-3-treated
mice as compared with PBS-treated mice or scramble
shRNA-treated mice (P < 0.05) (Figure 6a), suggesting intra-
tumoral ANT2 shRNA treatment has a strong antitumor effect
in vivo. One week after the final intratumoral injection of
respective ANT2 shRNA-1, shRNA-2 and shRNA-3 (day 32),
increased apoptotic cell death was detected by Terminal
deoxynucleotidyl transferase-mediated dUTP nick end-labe-
ling assay (Figure 6b) and the suppression of ANT2 was
detected by RT-PCR (data not shown) from the tumor tissues
obtained from ANT2 shRNA-treated mice. As a result, these
data indicate that the injection of ANT2 shRNA induces tumor
regressions associated with apoptosis in vivo.
Discussion
Energy generation by cells in the form of ATP can be achieved
in two main ways: oxidative phosphorylation in the mitochon-
dria, and glycolysis in the cytoplasm. Most normal cells mainly
utilize mitochondrial oxidative phosphorylation for ATP synthe-
sis but switch to glycolysis at lower oxygen tension [30-34].
Cancer cells, however, typically depend upon glycolysis (the
anaerobic breakdown of glucose to ATP) even in the presence
of adequate oxygen, and this phenomenon is called the War-
burg effect [35]. This increased glycolytic activity in cancer
cells is suspected to possibly be due to mitochondrial defects
and/or adaptation to a hypoxic tumor microenvironment [36-
39]. The inhibition of glycolysis in cancer cells has therefore
been suggested as a novel therapeutic strategy as well as a
method to overcome drug resistances associated with mito-
chondrial dysfunctions [40,41].
ANT exchanges ADP and ATP across the mitochondrial inner
membrane. Specifically, ANT1 and ANT3 export ATP pro-
duced by mitochondrial oxidative phosphorylation, whereas
ANT2 imports ATP produced by glycolysis into mitochondria
to supply the energy required for mitochondrial functions
[14,16]. In fact, ANT2 is mainly expressed in proliferative and
undifferentiated cells, and only trace amounts are existed in
differentiated cells, suggesting ANT2 can be an anticancer
therapeutic target. In addition to their role in energy
metabolism, ANTs are also involved in the formation of mito-
chondrial PTPC that mediates the nonspecific release of
apoptotic mediators. PTPC composed of ANTs, voltage-
dependent anion channel, cyclophilin D and Bcl2-Bax family
members is formed at the contact sites between mitochondrial
inner and outer membranes [42,43]. In previous reports, the
overexpression of ANT1 or ANT3 induced proapoptotic
effects, whereas overexpression of ANT2 did not [17,18]. In
addition, ANT2 suppression was also associated with cell
growth arrest and the increase of mitochondrial permeability
[9,11]. ANT2 is therefore considered an antiapoptotic onco-
protein that functions as an inhibitor of mitochondrial
membrane permeability such as Bcl2 and Bcl-xL, supporting
the idea to repress ANT2 as an anticancer strategy.
In the present study, we used DNA vector-based ANT2 siRNA
as a tool to inhibit ANT2 transcripts. It was found that DNA
vector-based ANT2 siRNA (shRNA) reduced ATP levels,
induced cell cycle G1 arrest and effectively induced apoptotic
cell death. Moreover, this apoptosis was accompanied by
mitochondrial membrane potential disruption, cytochrome c
release (data not shown) and caspase-3 activation. These
facts encouraged us to speculate that ANT2 repression may
disable ADP/ATP exchanges in mitochondrial membranes
and/or promote PTPC formation as well as apoptosis.
Figure 6
Adenine nucleotide translocator 2 shRNA inhibited tumor growth in  vivo Adenine nucleotide translocator 2 shRNA inhibited tumor growth in 
vivo. (a) In vivo experimental schedule and tumor regression induced 
by adenine nucleotide translocator (ANT) 2 shRNA. Balb/c nude mice 
were challenged with 5 × 106 MDA-MB-231 cells by subcutaneous 
injection into the right flanks and then treated with PBS, scramble 
shRNA or respective ANT2 shRNA-1, shRNA-2 and shRNA-3 vectors 
supplemented with Lipofectamine 2000 by intratumoral injection on 
day 21, day 23 and day 25 post challenge. Tumor sizes were measured 
by a caliper every week and volumes calculated using m1
2 × m2 × 
0.5236 (where m1 represents the short tumor axis and m2 the long axis) 
until day 56 post tumor challenge. (b) On day 32, tumor tissues were 
isolated and subjected to in situ apoptosis staining (Terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay). 
Bright green dots represent apoptotic bodies.Breast Cancer Research    Vol 10 No 1    Jang et al.
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Interestingly, we also observed that ANT2 shRNA treatment
upregulated proapoptotic Bax expression and downregulated
antiapoptotic Bcl-xL expression. We speculate that these
changes of gene expressions may contribute to the apoptotic
cell death induced by ANT2 shRNA. Bcl2 family members in
the mitochondrial membranes modulate the activities of ANTs,
and the Bcl2 family and ANT interactively participate in the for-
mation of PTPC [42,43]. No previous report, however, has
demonstrated that ANTs can affect the expressions of Bcl2
family members. The specific mechanisms underlying this
novel finding should be determined by further studies.
In contrast to our results, a recent study using siRNA oligonu-
cleotides to knockdown ANT2 showed that ANT2 suppres-
sion neither induced apoptosis nor had any discernible effect
on the mitochondrial network as well as the cell cycle. This
suppression, however, did result in chemosensitization and
increased mitochondrial transmembrane potential as well as
reactive oxygen species levels [12]. These different observa-
tions between our report and others might be due to the utili-
zation of different RNA interference technologies for
suppressing ANT2 gene expression. Chemically synthesized
siRNA is easily transfected into cancer cell lines and may be
more effective in silencing targeted genes than shRNA vector
[44]. siRNA synthesized in vitro, however, suppresses gene
expression only for a short period, while shRNA expression
vectors are transcribed and generated in vivo over long peri-
ods of time [45]. shRNA expression vectors therefore allow
more sophisticated investigations and have been widely used
for the functional analyses of genes and for anticancer thera-
pies [28,29]. For example, when siRNA and shRNA iRNA
technologies were utilized to knockdown the same gene, their
effects were different [46,47]. In the present study, ANT2
shRNA was found to be more effective for suppressing ANT2
(Figure 1c) and induced more cell death than ANT2 siRNA
(Figure 2e). As a result, our observations support that shRNAs
synthesized from DNA templates can induce robust, lasting
and near complete inhibitions of gene expression, suggesting
shRNA is more applicable to gene therapy than siRNA [27].
Another important finding from the present study was the
bystander effect induced by ANT2 shRNA treatment. We
demonstrated that this phenomenon was due to TNFα secre-
tion and TNF-receptor I upregulation from ANT2 shRNA-
treated cells. In addition, the cell death induced by the
bystander effect was mainly interpreted as necrosis. How the
expressions of TNFα and TNF-receptor I were induced by
ANT2 shRNA treatment, however, and why the bystander
effect induced necrotic cell death, are not known. More exper-
iments are needed to address these questions.
In a previous report, mitochondrial H+-ATPase inhibitor was
found to increase mitochondrial membrane permeability, to
decrease cellular ATP levels and to stimulate reactive oxygen
species production, subsequently leading to the activation of
stress-activated pathways and p21 induction [48]. In the
present study using ANT2 shRNA, we observed the disruption
of mitochondrial membrane potentials, ATP depletion, G1
stage arrest, apoptosis, the induction of TNFα and TNF-recep-
tor I as well as the upregulation of surface and intracellular
heat shock protein 70 expression in vitro (data not shown).
Among the many common observations between two sys-
tems, the induction of heat shock proteins is notable from the
immunological point of view. For example, the killing of tumor
cells by a HSV-tk (herpes simplex virus thymidine kinase) gan-
cyclovir system generated potent antitumor immunity and
induced heat shock protein expression [49]. Interestingly, the
induction of heat shock protein 70 expression induced the
infiltrations of T cells, macrophages and predominantly den-
dritic cells into tumors, as well as the intratumoral expressions
of T helper 1 cytokines such as IFNγ, TNFα and IL-12 [50,51].
We therefore speculate that ANT2 shRNA administration in
vivo might accelerate tumor cell death and increase immune
responses against tumors due to heat shock protein 70. A
study is now underway to investigate the mechanisms of
immune response associated with ANT2 shRNA in a wildtype
mouse tumor xenograft model.
In summary, the knockdown of ANT2 using ANT2 shRNA sys-
tems in breast cancer models induces apoptotic cell death
followed by ATP depletion, G1 stage arrest and the disruption
of mitochondrial membrane potentials in vitro and tumor
regression in vivo. In addition, the induction of TNFα and TNF-
receptor I in breast cancer cells mediated by ANT2 shRNA
generates the bystander effect that leads necrosis to the adja-
cent cells. We speculate that the antitumor effect mediated by
ANT2 shRNA in vivo is mainly due to its apoptotic functions.
The necrosis induced by the bystander effects, however, may
contribute to the tumor regression in vivo. We are currently try-
ing to evaluate the knockdown of ANT2 as a novel therapeutic
model for breast cancer treatment based on our interesting
observations.
Conclusion
This present study demonstrates that ANT2 silencing by DNA
vector-based iRNA effectively induces apoptotic cell death
and tumor growth inhibition in breast cancer models in vitro
and in vivo. We speculate that ANT2 silencing may offer a
novel cancer therapeutic strategy for breast cancer.
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